Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of SOF-SKN in Healthy Participants
NCT07072611Phase 1Completed
- Sponsor
- Noxopharm Limited
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SOF-SKN in cutaneous lupus erythematosus (CLE) (8 cohorts), sponsored by Noxopharm Limited. Primary endpoints: Percentage of Target Toxicities at 17 days, Percentage of Adverse Events at 17 days and 1 more. Started Jul 2025; status: completed.
02
Drugs
SOF-SKN
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT07072611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07072611.